Adenosine protects against suicidal erythrocyte death.
Suicidal death of erythrocytes or eryptosis is characterized by cell shrinkage and cell membrane scrambling leading to phosphatidylserine exposure at the erythrocyte surface. The cell membrane scrambling is triggered by an increase in cytosolic Ca(2+) activity and activation of protein kinase C (PKC). Phosphatidylserine exposure fosters adherence of affected erythrocytes to the vascular wall. Thus, microcirculation in ischemic tissues may be impaired by the appearance of eryptotic erythrocytes. Ischemia leads to release of adenosine, which in most tissues leads to vasodilation and protects against cell injury. The present experiments explored whether adenosine influences mechanisms underlying eryptosis. Erythrocyte phosphatidylserine exposure was estimated from annexin V binding, cell volume from forward scatter and cytosolic Ca(2+) activity from Fluo3 fluorescence. Glucose depletion (for 24 or 48 h) significantly increased annexin binding and decreased forward scatter, effects partially reversed by adenosine. The protective effect of adenosine reached statistical significance (s.d.) at > =30 microM. Low Cl(-) solution (Cl(-) exchanged by gluconate for 24 h) similarly increased annexin binding and decreased forward scatter, effects again reversed by adenosine (s.d. at > or =10 and 30 microM, respectively). Similarly, phosphatase inhibitor okadaic acid (OA, 1 microM) and PKC activator phorbol 12-myristate-13-acetate (PMA, 3 microM) significantly enhanced annexin binding and decreased forward scatter. Adenosine significantly blunted the effects of OA and PMA on annexin V binding (s.d. at > or =30 and 10 microM, respectively) and the effect of OA on forward scatter (s.d. at > or =10 microM). In conclusion, adenosine inhibits eryptosis by a mechanism presumably effective downstream of PKC. The effect may participate in the maintenance of microcirculation in ischemic tissue.
Niemoeller
Olivier M
OM
Department of Physiology, University of Tübingen, Tübingen, Germany.
Bentzen
Peter J
PJ
Lang
Elisabeth
E
Lang
Florian
F
D000241:Adenosine / Q000494:pharmacology*; D017304:Annexin A5 / Q000097:blood; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D002118:Calcium / Q000097:blood; D002712:Chlorides / Q000494:pharmacology; D004905:Erythrocyte Aging / Q000187:drug effects* / Q000502:physiology; D004912:Erythrocytes / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D019319:Okadaic Acid / Q000494:pharmacology; D010718:Phosphatidylserines / Q000097:blood; D011493:Protein Kinase C / Q000097:blood
D017304:Annexin A5; D002712:Chlorides; D010718:Phosphatidylserines; D019319:Okadaic Acid; D011493:Protein Kinase C; D005947:Glucose; D000241:Adenosine; D002118:Calcium